ReviewNature reviews. Disease primers2021
Cholangiocarcinoma.
Review in Nature reviews. Disease primers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06381648 (An Exosome-based Liquid Biopsy Signature for Pre-operative Identification of Lymph Node Metastasis in Patients With Intrahepatic Cholangiocarcinoma), which is not on this map. Cited by 529 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Exosome-based Liquid Biopsy Signature for Pre-operative Identification of Lymph Node Metastasis in Patients With Intrahepatic Cholangiocarcinoma
Who cites it
529 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Comparative Diagnostic Accuracy of Cholangioscopy-Based Modalities for Indeterminate Biliary Strictures: A Systematic Review and Network Meta-Analysis.Digestive diseases and sciences · 2026Pooled it
- Expression of COL6A1 in Tumor Matrix of Cholangiocarcinoma and Its Mechanism of Tumor Progression.Cancer reports (Hoboken, N.J.) · 2026Pooled it
- Bile Cell-Free DNA as a Tumor-Proximal Source for Molecular Profiling of Biliary Tract Cancer: A Systematic Review and Meta-Analysis.Molecular diagnosis & therapy · 2026Pooled it
- Safety evaluation of TOPAZ-1 and KEYNOTE-966 regimens in metastatic biliary tract cancer: a systematic review and meta-analysis.Clinical & experimental metastasis · 2026Pooled it
- Pooled it
- First-Line Chemotherapy Regimens for Unresectable Locally Advanced or Metastatic Biliary Tract Cancer: A Systematic Review and Bayesian Network Meta-Analysis.JAMA network open · 2026Pooled it
- Trial
- Comparative impact of tertiary lymphoid structures and tumor-infiltrating lymphocytes in cholangiocarcinoma.Journal for immunotherapy of cancer · 2025Trial
- Immunotherapy impact of macrophage glycosylation on cholangiocarcinoma and its prognostic and immune microenvironment significance.Human vaccines & immunotherapeutics · 2026Article
- Glucosamine induces apoptosis of cholangiocarcinoma cells by suppressing high-mannose typeFuture science OA · 2026Article
- Development and Validation of a Crotonylation-Related Prognostic Risk Model for Cholangiocarcinoma Based on Integrative Transcriptome Analysis.Digestive diseases and sciences · 2026Article
- Serum proteomic profiling identifies pathways and protein signatures associated with earlyRSC advances · 2026Article
- Imaging of mass-forming intrahepatic cholangiocarcinoma: from detection to personalized treatments.Abdominal radiology (New York) · 2026Review
- Cholangiocarcinoma:Unveiling the cold tumor microenvironment and strategies for immune rejuvenation.Oncogene · 2026Review
- Spontaneous Hepatobiliary Disease in a Breeding Colony of Aotus spp.Journal of medical primatology · 2026Article
- Hepatitis B virus pregenomic RNA is associated with malignant phenotypes and postoperative survival in HBV-related intrahepatic cholangiocarcinoma.Infectious agents and cancer · 2026Article
- AURKB drives aggressive phenotype and clinicopathological progression in cholangiocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Shared genetic regulators and diagnostic biomarkers in gallbladder stone and cholangiocarcinoma: A comprehensive comparative transcriptomic analysis.Translational oncology · 2026Article
- Development and frontier trends of research on the gut microbiota and cholangiocarcinoma.Surgery open science · 2026Article
- A practical nomogram for predicting survival in patients with extrahepatic cholangiocarcinoma: a population-based cohort study.Journal of gastrointestinal oncology · 2026Article
469 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cholangiocarcinoma (CCA) is a highly lethal adenocarcinoma of the hepatobiliary system, which can be classified as intrahepatic, perihilar and distal. Each anatomic subtype has distinct genetic aberrations, clinical presentations and therapeutic approaches. In endemic regions, liver fluke infection is associated with CCA, owing to the oncogenic effect of the associated chronic biliary tract inflammation. In other regions, CCA can be associated with chronic biliary tract inflammation owing to choledocholithiasis, cholelithiasis, or primary sclerosing cholangitis, but most CCAs have no identifiable cause. Administration of the anthelmintic drug praziquantel decreases the risk of CCA from liver flukes, but reinfection is common and future vaccination strategies may be more effective. Some patients with CCA are eligible for potentially curative surgical options, such as resection or liver transplantation. Genetic studies have provided new insights into the pathogenesis of CCA, and two aberrations that drive the pathogenesis of non-fluke-associated intrahepatic CCA, fibroblast growth factor receptor 2 fusions and isocitrate dehydrogenase gain-of-function mutations, can be therapeutically targeted. CCA is a highly desmoplastic cancer and targeting the tumour immune microenvironment might be a promising therapeutic approach. CCA remains a highly lethal disease and further scientific and clinical insights are needed to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.